Kessler Investment Group LLC trimmed its stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 37.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 38,108 shares of the company stock after selling 23,227 shares during the quarter. Johnson & Johnson makes up 3.7% of Kessler Investment Group LLC’s portfolio, making the stock its 8th largest position. Kessler Investment Group LLC’s holdings in Johnson & Johnson were worth $ 6,519,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in JNJ. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $ 34,000. Iron Horse Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after purchasing an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after purchasing an additional 218 shares in the last quarter. Retirement Group LLC boosted its holdings in shares of Johnson & Johnson by 20.5% in the 4th quarter. Retirement Group LLC now owns 447 shares of the company stock worth $ 77,000 after purchasing an additional 76 shares in the last quarter. Finally, Castle Financial & Retirement Planning Associates Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $ 91,000. Institutional investors own 68.78% of the company stock.
Shares of NYSE: JNJ opened at $ 168.19 on Wednesday. Johnson & Johnson has a 52-week low of $ 155.72 and a 52-week high of $ 186.69. The firm has a market capitalization of $ 442.58 billion, a P / E ratio of 22.67, a P / E / G ratio of 3.41 and a beta of 0.66. The stock has a 50 day moving average price of $ 178.83 and a 200-day moving average price of $ 172.64. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.
Johnson & Johnson (NYSE: JNJ – Get Rating) last announced its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same quarter in the prior year, the company earned $ 2.59 EPS. The business’s revenue was up 5.0% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were given a $ 1.13 dividend. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 annualized dividend and a dividend yield of 2.69%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s dividend payout ratio is currently 60.92%.
In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total transaction of $ 1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company stock, valued at approximately $ 2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at $ 12,336,803. The disclosure for this sale can be found here. Insiders sold a total of 101,842 shares of company stock valued at $ 18,069,079 in the last three months. Corporate insiders own 0.35% of the company stock.
JNJ has been the subject of several analyst reports. Citigroup dropped their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Raymond James increased their target price on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Credit Suisse Group increased their target price on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the company from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Finally, Bank of America assumed coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $ 190.50.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.